Biotech | February 28, 2026
Synthekine teams up with Merck to test breakthrough lung cancer combo
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Over 8.8?million Indians aged 60 and above currently live with dementia,
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Subscribe To Our Newsletter & Stay Updated
